Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Thomas R. Kosten, MD, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00435370
First received: February 13, 2007
Last updated: August 12, 2014
Last verified: August 2014
Results First Received: August 1, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Pharmacodynamics Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Smoking Cessation
Schizophrenia
Interventions: Drug: Tropisetron
Drug: Placebo
Drug: Risperidone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The recruitment period began in May 2006 and ended in April 2011. Participants were approached for participation in this study after being hospitalized for at least 2 weeks if they were schizophrenic and capable of providing written informed consent.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
After signing informed consent for participation in the study, subjects were interviewed by study doctor and all medical and psychiatric data were reviewed prior to admitting the subject and beginning medication.

Reporting Groups
  Description
Tropisetron Tropisetron (10mg/day) + risperidone(6mg/day)
Placebo Placebo + risperidone (6mg/day)

Participant Flow:   Overall Study
    Tropisetron     Placebo  
STARTED     90     89 [1]
COMPLETED     68     69 [2]
NOT COMPLETED     22     20  
Adverse Event                 8                 8  
Withdrawal by Subject                 10                 10  
Antipsychotic medication changed                 4                 2  
[1] The recruitment restarted in August, 2010.
[2] The entire recruitment has been completed in December, 2011.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Tropisetron Tropisetron (10mg/day) + risperidone(6mg/day)
Placebo Placebo + risperidone (6mg/day)
Total Total of all reporting groups

Baseline Measures
    Tropisetron     Placebo     Total  
Number of Participants  
[units: participants]
  90     89     179  
Age  
[units: participants]
     
<=18 years     0     0     0  
Between 18 and 65 years     90     89     179  
>=65 years     0     0     0  
Age  
[units: years]
Mean ± Standard Deviation
  28.8  ± 9.2     28.3  ± 9.9     28.6  ± 9.6  
Gender  
[units: participants]
     
Female     52     50     102  
Male     38     39     77  
Region of Enrollment  
[units: participants]
     
China     90     89     179  



  Outcome Measures

1.  Primary:   Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Cognition Domains   [ Time Frame: end of 12 wk treatment ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Since all participants were the first episode and drug naive patients, some participants quit before the completion of the entire clinical trial


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Thomas R. Kosten
Organization: Baylor College of Medicine
phone: (713) 794-7032
e-mail: kosten@bcm.edu


No publications provided by Baylor College of Medicine

Publications automatically indexed to this study:

Responsible Party: Thomas R. Kosten, MD, Baylor College of Medicine
ClinicalTrials.gov Identifier: NCT00435370     History of Changes
Other Study ID Numbers: U01 MH079639, U01MH079639
Study First Received: February 13, 2007
Results First Received: August 1, 2013
Last Updated: August 12, 2014
Health Authority: United States: Federal Government